Cost-effectiveness of Left Ventricular Assist Devices (LVADs) as destination therapy in the UK: An economic modelling study
Our analysis found that LVADs are not cost-effective as destination therapy in the UK if a willingness to pay threshold of £50,000 per QALY gained or disease severity modifiers, were applied. Robust data on ongoing costs for LVAD and medical management are needed.
Authors
- Tuba Saygın Avşar (ORCID: https://orcid.org/0000-0002-4143-3852)
- Sophie Beese (ORCID: https://orcid.org/0000-0001-6329-0779)
- Pelham Barton (ORCID: https://orcid.org/0000-0002-0519-3724)
- David Quinn (ORCID: https://orcid.org/0000-0003-2465-305X)
- Louise Jackson (ORCID: https://orcid.org/0000-0001-8492-0020)
- Hoong Sern Lim (ORCID: https://orcid.org/0000-0002-6569-1805)
- Malcolm J Price (ORCID: https://orcid.org/0000-0002-7352-3027)
- David J. Moor
Institutions
- Canadian University of Dubai (AE)
- University College London (GB)
- University of Birmingham (GB)
Publication Details
- Journal
- PLoS ONE
- Published
- 2024-12-04
- DOI
- https://doi.org/10.1371/journal.pone.0312912
- Citations
- 4
- Primary Topic
- Mechanical Circulatory Support Devices
- Type
- article
- Field-Weighted Citation Impact
- 0.74
Funders
- National Institute for Health and Care Research
- Health Technology Assessment Programme